Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

KalVista Pharmaceuticals Ltd.

Division of KalVista Pharmaceuticals Inc.
www.kalvista.com

Latest From KalVista Pharmaceuticals Ltd.

Appointments: Bayer, Mustang, Modus, GammaDelta, Poxel, Metrion and Renova.

This week's roundup includes CEO appointments by various companies including Mustang Bio, GammaDelta and Modus Therapeutics and other high-level appointments by Bayer, Renova, Metrion and Poxel.

Appointments BioPharmaceutical

Start-Up Execs On The Move, September 2015

Recent executive-level hires and director appointments at venture capital firms and biopharma and medtech start-ups.

BioPharmaceutical Medical Device

Venture Funding Deals, September 2015

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a monthly review of emerging In Vitro Diagnostic, Medical Device, and Pharmaceutical companies that have received venture funding. This month’s column covers deals announced July through August 2015.

BioPharmaceutical Medical Device

KalVista’s Novel DME Approach Moves To Clinical Trials

Britain’s KalVista believes it is pioneering the use of kallikrein inhibitors for diabetic macular edema, including orally active derivatives, as it moves its lead compound into U.S. clinical trials.

BioPharmaceutical United Kingdom
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • KalVista Pharmaceuticals Inc.
  • Senior Management
  • T. Andrew Crockett, CEO
    Benjamin L Palleiko, CFO
    Christopher M Yea, PhD, Chief Dev. Officer
  • Contact Info
  • KalVista Pharmaceuticals Ltd.
    Phone: (857) 241-3897
    One Kendall Sq., Bldg. 200, Ste. 2203
    Cambridge, 02139
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register